Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR Surgical Company updated the compensation of Deborah Andrews, its Interim Co-Chief Executive Officer and Chief Financial Officer. Effective June 8, 2026, her annual base salary increases from $512,000 to $575,000. Her target annual cash bonus also rises from 55% to 60% of base salary, reflecting a review of market data and her contributions to the company’s strategic and operational objectives.
STAAR Surgical interim Co-CEO and CFO Deborah J. Andrews reported equity compensation activity tied to performance stock units that vested on May 15, 2026. Two tranches of performance stock units under the 2025 PSU Program settled into 10,466 and 5,233 shares of common stock after the Compensation Committee certified performance results.
To cover tax obligations on these vestings, the company withheld 3,755 and 1,877 shares, reported as tax-withholding dispositions at about $32.07 per share. After these non‑market transactions, Andrews directly held 15,297 shares of STAAR Surgical common stock. The filing reflects routine compensation and tax withholding, not open‑market buying or selling.
STAAR Surgical’s interim co-CEO and President & COO Warren Foust reported routine equity compensation activity tied to performance stock units on May 15, 2026. Several tranches of 2025 performance stock units vested and were settled into common shares, with a portion of the shares withheld to cover tax obligations at $32.07 per share. Following these transactions, Foust directly held 81,579 shares of common stock.
STAAR Surgical Chief Development Officer Magda Michna reported compensation-related share activity tied to performance stock units. On May 15, 2026, multiple tranches of 2025 Performance Stock Units vested and were settled into a total of 19,795 shares of common stock. To cover tax obligations, 9,703 shares were withheld at a price of $32.07 per share. After these settlements and withholdings, Michna directly holds 38,093 shares of common stock and 10,997 remaining performance stock units.
STAAR Surgical reported a strong turnaround for the quarter ended April 3, 2026. Net sales rose to $93.5 million, up 119.6% from a year earlier, driven mainly by China, where distributor sales reached $47.4 million and the EVO+ ICL launch was well received. Gross margin improved to 73.6% from 65.8% as prior cost-cutting and the Swiss manufacturing ramp began to benefit unit costs.
The company moved from a net loss of $54.2 million to net income of $5.2 million, or $0.10 per diluted share, even after $6.7 million of merger- and cooperation-related expenses and $2.7 million of restructuring charges. Operating cash flow was negative $21.7 million due to higher receivables and seasonal payments, but cash and investments remained solid at $163.9 million with working capital of $251.4 million.
Results highlight both rapid growth and concentration risk: China distributors represented 51% of net sales and 57% of trade receivables. Management expects to supply all EVO and EVO+ ICLs for China from Switzerland by the end of 2026, eliminating tariff exposure while continuing to focus on cost discipline and profitable growth.
STAAR Surgical reported a sharp turnaround in first quarter 2026. Net sales reached $93.5 million, up 119.6% from $42.6 million a year earlier, driven mainly by a recovery in China and double-digit growth in the Americas.
Gross margin improved to 73.6% from 65.8%, and the company moved from a net loss of $54.2 million to net income of $5.2 million, or $0.10 per diluted share. Adjusted EBITDA shifted from a loss of $26.3 million to a gain of $24.4 million, reflecting higher gross profit and lower operating expenses.
China net sales grew to $47.4 million, helped by strong demand for EVO+ ICL and normalized distributor inventory, while net sales excluding China were $46.1 million, up 6.0%. Cash, cash equivalents, and investments totaled $163.9 million at April 3, 2026, and the company reported no outstanding debt.
Point72 Asset Management and related filers report a 5.2% beneficial ownership stake in STAAR Surgical Company as of May 11, 2026. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over 2,591,498 shares of common stock (CUSIP 852312305). The stake is held in investment funds managed by Point72; the reporting persons disclaim direct ownership.
STAAR Surgical's Interim Co-CEO and President & COO Warren Foust reported a tax-related share disposition linked to previously granted restricted stock units. On May 8, 2026, 3,448 shares of common stock were withheld at $26.69 per share to satisfy tax obligations when RSUs vested. These RSUs were part of a grant made on May 8, 2023, vesting in three equal installments of 6,777 shares on May 8 of 2024, 2025, and 2026. After this tax-withholding event, Foust directly held 66,917 shares of STAAR Surgical common stock.
STAAR Surgical’s Chief Development Officer Magda Michna reported a routine tax-related share disposition. On May 8, 2026, 1,680 shares of common stock were withheld at $26.69 per share to cover taxes on previously granted restricted stock units that vested on that date.
The RSUs were granted on May 8, 2023 and vested in three roughly equal annual installments through May 8, 2026. After the tax withholding, Michna directly owns 32,691 shares of STAAR Surgical common stock. The filing also corrects a prior typo in reported holdings, confirming the correct earlier total was 29,688 shares.